Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4104169
Max Phase: Preclinical
Molecular Formula: C16H23IN6O8S
Molecular Weight: 586.37
Molecule Type: Small molecule
Associated Items:
ID: ALA4104169
Max Phase: Preclinical
Molecular Formula: C16H23IN6O8S
Molecular Weight: 586.37
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@H](O)C(=O)NS(=O)(=O)OC[C@H]1O[C@@H](n2cnc3c(N)nc(I)nc32)[C@H](O)[C@@H]1O
Standard InChI: InChI=1S/C16H23IN6O8S/c1-6(2)3-7(24)14(27)22-32(28,29)30-4-8-10(25)11(26)15(31-8)23-5-19-9-12(18)20-16(17)21-13(9)23/h5-8,10-11,15,24-26H,3-4H2,1-2H3,(H,22,27)(H2,18,20,21)/t7-,8+,10+,11+,15+/m0/s1
Standard InChI Key: WHBKHJPUBVIUDX-JVEUSOJLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 586.37 | Molecular Weight (Monoisotopic): 586.0343 | AlogP: -1.58 | #Rotatable Bonds: 8 |
Polar Surface Area: 212.01 | Molecular Species: ACID | HBA: 13 | HBD: 5 |
#RO5 Violations: 2 | HBA (Lipinski): 14 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 2.71 | CX Basic pKa: 2.13 | CX LogP: -1.08 | CX LogD: -1.51 |
Aromatic Rings: 2 | Heavy Atoms: 32 | QED Weighted: 0.18 | Np Likeness Score: 0.81 |
1. Yoon S, Kim JH, Koh Y, Tran PT, Ann J, Yoon I, Jang J, Kim WK, Lee S, Lee J, Kim S, Lee J.. (2017) Discovery of simplified leucyladenylate sulfamates as novel leucyl-tRNA synthetase (LRS)-targeted mammalian target of rapamycin complex 1 (mTORC1) inhibitors., 25 (15): [PMID:28625715] [10.1016/j.bmc.2017.06.002] |
2. Yoon S, Kim SE, Kim JH, Yoon I, Tran PT, Ann J, Kim C, Byun WS, Lee S, Kim S, Lee J, Lee J.. (2019) Structure-activity relationship of leucyladenylate sulfamate analogues as leucyl-tRNA synthetase (LRS)-targeting inhibitors of Mammalian target of rapamycin complex 1 (mTORC1)., 27 (6): [PMID:30755350] [10.1016/j.bmc.2019.01.037] |
3. Yoon S,Kim JH,Kim SE,Kim C,Tran PT,Ann J,Koh Y,Jang J,Kim S,Moon HS,Kim WK,Lee S,Lee J,Kim S,Lee J. (2016) Discovery of Leucyladenylate Sulfamates as Novel Leucyl-tRNA Synthetase (LRS)-Targeted Mammalian Target of Rapamycin Complex 1 (mTORC1) Inhibitors., 59 (22): [PMID:27933890] [10.1021/acs.jmedchem.6b01190] |
Source(1):